AquaFit Official Website › Blog › Can You Trust A Supplement That Lists No Ingredients?

Can You Trust A Supplement That Lists No Ingredients?

Reviewed by Dr. Chioma Okafor-Mbah, MD

This is the post that costs this product something. It is written by the desk that would take your money, and it ends with a recommendation that is not simply yes.

What exactly is missing

It is worth being precise, because “no ingredients listed” sounds like an exaggeration and is not one. Here is the full list of what a buyer normally checks and what this product publishes for each.

Eight rows, eight absences. What the label does print is a product name, the phrase clinically studied ingredients, three support lines, a capsule count and the words dietary supplement. What it does not print is anything you could take to a pharmacist.

Is that even allowed?

The short answer is that a finished bottle sold in the United States is required to carry a Supplement Facts panel and an ingredient statement. The FDA publishes the format and what it must contain (the FDA labeling guide).

So the honest framing of the problem is this: the question is not whether a panel exists, it is whether it is published where a buyer can read it before paying. On this product it is not. The bottle front carries none, and the distributor’s sales page publishes none. A buyer therefore commits money before seeing the one document that would let them evaluate what they are buying.

What that means for this website

It means every page here prints “not published” rather than an estimate, and it means we say plainly that a bottle in your hand may carry more than the sales page does. If yours has a printed panel, it is the authority and this website is not. Photograph it and send it to [email protected]. It would change five pages here and we would publish it the same week.

The picture that makes the point

Two pieces of artwork for one product, naming twelve things between them, agreeing on almost none of them, over a bottle that names nothing. That is the clearest single illustration of why marketing imagery and a panel are different categories of information.

Why this matters more than a small dose would

On most products in this family the argument is arithmetic. The label prints a number, the trials used a larger one, and a reader can weigh the two and decide. Here there is nothing to weigh, which sounds like a smaller problem and is a larger one.

• A pharmacist cannot clear it. Interaction screening works by reading a list. With no list, the honest professional answer is that they cannot check it, and that answer is correct rather than unhelpful.
• An allergy cannot be anticipated. The pack carries gluten-free and dairy-free seals. Those address two allergens and are not an allergen statement.
• Nothing can be compared. Not against a competitor, not against a food, not against the cost of the same compounds bought singly. Comparison is a buyer's main defence and it has been removed.
• A symptom cannot be looked up. If something changes in week two, there is no panel to check it against, which lowers rather than raises the threshold for asking a clinician.

What the wider category record says

None of the following is a statement about this product, which has no adverse history we are aware of. It is the environment the product is sold in, and it explains why a buyer is right to want a label they can read.

Read those five rows and then read the eight absences again. The connection is not that this product is dangerous. It is that transparency is the main defence a buyer has in a category where the regulatory floor is low, and this label has declined to offer it.

What you do get, which is not nothing

An article that stops at the criticism is as unbalanced as an advertisement that omits it. Four things this product does publish, and they are the four a retail desk can actually be held to.

• A lot code. AF-26/BR-5104, printed on the base of the bottle with the best-before date, and matchable against the order paperwork by telephone.
• Two street addresses. An office and a separate returns address, both in New York, printed in the footer of every page.
• A staffed telephone line. +1 (888) 254-0425, seven days. One of the eight published reviewers wrote three words about it: phone picked up.
• A 60-day refund window. Long enough to cover the period the seller’s own summary says most reports of a change fall in.

Those four are worth something. They are also all about the seller rather than about the capsule, and a reader is entitled to decide that the capsule is the part they cared about.

So should you buy it?

Here is the answer from the desk that would take the money, with the awkward half left in.

Probably not, if you read labels. If you are the kind of buyer who turns a bottle over before paying, this product will frustrate you within a minute and there are competitors that publish a panel. That is a legitimate reason to buy something else and we would rather write it here than have you discover it after paying.

Possibly, if what you want is a supported daily routine. If the panel is not the part you were going to use, what is left is a once-daily capsule from a desk with a telephone number, a traceable lot and sixty days to change your mind. That is a real offer, and it is a better one than most listings in this category.

Definitely not, if you are on prescription medication and have not asked. Speak to the prescriber first, and tell them the label names nothing. It changes what they can check.

What we asked the desk, and what it said

Before publishing any of this, the questions were put to the order desk directly. The answers are printed as given, because a page complaining about transparency should demonstrate some.

Five of six answers are some version of no, and the sixth is the one the desk can actually deliver. That is an honest summary of what a retail desk is able to be responsible for when the manufacturer has not published a panel, and it is better said out loud than discovered on a telephone call.